In this webinar Josh Apgar, PhD discusses Early Feasibility Assessment (EFA), a quantitative approach to early discovery, to help predict whether a therapeutic has a reasonable chance of success. In this presentation, we’ll…
Explore how our ESG strategy is crafting impactful, lasting change in our ESG Report.
RADNOR, Pa. — October 28, 2024 — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment…
Expert nonclinical drug development consulting services, from hit to lead identification, into first-in-human studies and regulatory strategy.
Our nonclinical & clinical DMPK & ADME Consulting Services support a wide range of offerings to advance early drug development.
Certara’s expert CMC consultants provide CMC support across all phases of drug development, from early preclinical development to post-market activities.
Your biotech company has just submitted the marketing application for your first drug product. It’s a moment of celebration after years of hard work! But you know that the reviewers’…
Clients are invited to join Certara at this two-day event to further explore and connect on the future of drug development RADNOR, PA – OCTOBER 24, 2024 – Certara, Inc….
Read this guide to find out the 5 common CDISC SDTM implementation challenges and the best practice solutions to each.
This free guide explores how to automate CRF annotations, the benefits of automation, and the industry requirements you need to know.
© 2025 Certara. All Rights Reserved. | Privacy policy
